Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Intermittent Linezolid in Septic Shock
NCT05813951Unknown
- Sponsor
- Ain Shams University
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of linezolid in septic shock (2 arms), sponsored by Ain Shams University. Primary endpoint: Occurrence of medical cure at 7 days. Status: unknown.
02
Drugs
linezolid
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT05813951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813951.